LON:DNLDiurnal Group Share Price, Forecast & News

GBX 31

0.00 (0.00 %)

(As of 05/25/2020 06:16 AM ET)

Add

Compare

Today's Range

Now: GBX 31▼

50-Day Range

27.50

MA: GBX 30.10▼

33.50

52-Week Range

Now: GBX 31▼

Volume2,897 shs

Average Volume7,428 shs

Market Capitalization£37.71 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Diurnal Group.

2.8 Community Rank

Outperform Votes
Diurnal Group has received 197 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Diurnal Group has received 154 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Diurnal Group has received 56.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Diurnal Group and other stocks. Vote “Outperform” if you believe DNL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DNL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Diurnal Group does not currently pay a dividend.
Dividend Growth
Diurnal Group does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Diurnal Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought £9,541.68 in company stock and sold GBX 0 in company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Diurnal Group are expected to grow in the coming year, from GBX (27.06) to GBX 0 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Diurnal Group is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Diurnal Group is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Diurnal Group has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.29 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolLON:DNL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.diurnal.co.uk

Phone+44-29-20682069

Debt

Debt-to-Equity Ratio0.77

Current Ratio4.46

Quick Ratio3.80

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£2.01 million

Price / Sales18.81

Cash FlowGBX 5.40 per share

Price / Cash Flow5.74

Book ValueGBX 8.60 per share

Price / Book3.60

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees23

Outstanding Shares121,633,000

Market Cap£37.71 million

Next Earnings DateN/A

OptionableNot Optionable

Receive DNL News and Ratings via Email

Sign-up to receive the latest news and ratings for DNL and its competitors with MarketBeat's FREE daily newsletter.

Diurnal Group (LON:DNL) Frequently Asked Questions

How has Diurnal Group's stock been impacted by COVID-19 (Coronavirus)?

Diurnal Group's stock was trading at GBX 34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DNL stock has decreased by 8.8% and is now trading at GBX 31. View which stocks have been most impacted by Coronavirus.

How were Diurnal Group's earnings last quarter?

Diurnal Group PLC (LON:DNL) posted its quarterly earnings results on Tuesday, February, 11th. The company reported ($4.70) earnings per share (EPS) for the quarter. View Diurnal Group's earnings history.

Has Diurnal Group been receiving favorable news coverage?

News stories about DNL stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Diurnal Group earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutDiurnal Group.

Who are some of Diurnal Group's key competitors?

Some companies that are related to Diurnal Group include Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Shield Therapeutics (STX), Supreme Cannabis (FIRE), Althea Group (AGH), WeedMD (WMD), Delta 9 Cannabis (NINE), Depomed (ASRT), Flowr (FLWR), MMJ Group (MMJ), Venture Life Group (VLG), Biosyent (RX), Auscann Group (AC8) and Acerus Pharmaceuticals (ASP). View all competitors.

What other stocks do shareholders of Diurnal Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO), SRC Energy (SRCI), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF) and AcelRx Pharmaceuticals (ACRX).

Who are Diurnal Group's key executives?

Diurnal Group's management team includes the following people:

Dr. Martin Whitaker B.Sc., BSc, Ph.D., CEO & Exec. Director
Mr. Richard Edward Bungay BSc, ACA, CFO,Director & Company Sec. (Age 50)
Prof. Richard Ross, Chief Scientific Officer & Exec. Director
Mr. Michael Withe, Commercial Director
Mr. John Porter, Medical Director

What is Diurnal Group's stock symbol?

Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."

How do I buy shares of Diurnal Group?

Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Diurnal Group's stock price today?

One share of DNL stock can currently be purchased for approximately GBX 31.

How big of a company is Diurnal Group?

Diurnal Group has a market capitalization of £37.71 million and generates £2.01 million in revenue each year. Diurnal Group employs 23 workers across the globe.

What is Diurnal Group's official website?

The official website for Diurnal Group is www.diurnal.co.uk.

How can I contact Diurnal Group?

Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.

This page was last updated on 5/25/2020 by MarketBeat.com Staff